Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study
European Journal of Neurology · 2026-06 · 33 (6)
DOI: 10.1111/ene.70652 ↗Abstract
ABSTRACT Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies. The resulting activation of the immune system may lead to neurological immune‐related adverse events (n‐irAEs). Here, we retrospectively characterized severe n‐irAEs in a monocentric cohort. Methods We screened an in‐house registry of the Medical University of Vienna, Austria, including all patients treated with ICIs between 2007 and 2023. Patients who underwent a neurological evaluation were identified, and their medical records were reviewed. Cases with severe (i.e., grade ≥ 3) n‐irAEs were analyzed. We report clinical and demographic characteristics, neurological manifestations, treatment and outcomes. Results Ten out of 2043 screened patients (i.e., 0.5%) developed severe n‐irAEs. In most cases ( n = 7), neurological manifestations involved the neuromuscular system and/or peripheral nerves, including myasthenia/myositis ( n = 5), polyneuropathy ( n = 1), and facial nerve palsy ( n = 1). Central nervous system involvement included aseptic meningitis, myelitis, and stroke (each n = 1). The number of ICI cycles prior to n‐irAE onset varied, with a median of 3 cycles (range 1–43). The median time from the last infusion to symptom onset was 7 days (range 2–24). n‐irAEs led to ICI discontinuation and/or immunomodulatory treatments in 9 patients. Clinical improvement was observed in 7 of 10 cases. No deaths were attributed to ICI‐related toxicity. Conclusion Our findings indicate that severe n‐irAEs are rare. Nonetheless, clinicians should remain vigilant for delayed‐onset neurotoxicity, even after long treatment exposure. Most patients showed clinical improvement following ICI discontinuation and/or immunomodulatory treatments.
EUVIMED